p53 (17-26)
p53 (17-26) is a peptide derived from the P53 MDM2 binding domain, with a Kd of 50 nM for MDM2. p53 (17-26) causes cell lysis by damaging cancer cells and nuclear membranes, and induces cancer cell necrosis. p53 (17-26) exhibits antitumor activity and is applicable to research related to pancreatic cancer.
For research use only. We do not sell to patients.
- CAS No.: 488118-64-5
- Formula: C60H90N12O17
- Molecular Weight:1251.43
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
In Vitro
In Vivo
p53 (17-26) (1-20 mg; subcutaneous osmotic pump; 14 days) dose-dependently inhibits the growth of established subcutaneous xenograft pancreatic cancer in nude mice[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Hsd:Athymic Nu/Nu (7-8 weeks old, 22-24 g, i.p. xenotransplantation of BMRPA1.Tuc3 pancreatic carcinoma cells)[2]
-
Dosage:2 mg/mouse
-
Administration:subcutaneous osmotic pump; constant rate 0.25 μL/hr; 14 days
-
Result:Prevented ascites or liver metastasis on day 21.
Contained no viable tumor cells in peritoneal lavage fluid, only macrophages and lymphocytes that did not grow in culture.
-
Animal Model:Hsd:Athymic Nu/Nu (7-8 weeks old, 22-24 g, s.c. xenotransplanted BMRPA1.Tuc3 pancreatic carcinoma cells grown to 40-260 mg before treatment)[2]
-
Dosage:20 mg/mouse; 10 mg/mouse; 1 mg/mouse
-
Administration:subcutaneous osmotic pump; 14 days
-
Result:Reduced average tumor size.
Inhibited post-treatment tumor growth.
Caused no weight loss or toxicity in treated mice.
Chemical Information
-
CAS No. 488118-64-5
-
Molecular Weight 1251.43
-
Formula C60H90N12O17
-
Sequence
Glu-Thr-Phe-Ser-Asp-Leu-Trp-Lys-Leu-Leu
-
Sequence Shortening
ETFSDLWKLL
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Solvent & Solubility
In Vitro
H2O
Peptide Solubility and Storage Guidelines:
1. Calculate the length of the peptide.
2. Calculate the overall charge of the entire peptide according to the following table:
| Contents | Assign value | |
|---|---|---|
| Acidic amino acid | Asp (D), Glu (E), and the C-terminal -COOH. | -1 |
| Basic amino acid | Arg (R), Lys (K), His (H), and the N-terminal -NH2 | +1 |
| Neutral amino acid | Gly (G), Ala (A), Leu (L), Ile (I), Val (V), Cys (C), Met (M), Thr (T), Ser (S), Phe (F), Tyr (Y), Trp (W), Pro (P), Asn (N), Gln (Q) | 0 |
3. Recommended solution:
| Overall charge of peptide | Details |
|---|---|
| Negative (<0) |
1. Try to dissolve the peptide in water first. 2. If water fails, add NH4OH (<50 μL). 3. If the peptide still does not dissolve, add DMSO (50-100 μL) to solubilize the peptide. |
| Positive (>0) |
1. Try to dissolve the peptide in water first. 2. If water fails, try dissolving the peptide in a 10%-30% acetic acid solution. 3. If the peptide still does not dissolve, try dissolving the peptide in a small amount of DMSO. |
| Zero (=0) |
1. Try to dissolve the peptide in organic solvent (acetonitrile, methanol, etc.) first. 2. For very hydrophobic peptides, try dissolving the peptide in a small amount of DMSO, and then dilute the solution with water to the desired concentration. |
Protocols
-
Protein Extraction
Protein extraction uses physical, chemical or biological methods, such as ultrasonic disruption, salting out, cell lysis, electrophoresis, etc., to destroy the cell membrane structure and to separate the proteins from different components according to their characteristics.
-
Subcutaneous Cell-Line-Derived Xenograft
Subcutaneous cell-line-derived xenograft (CDX) models are established by implanting cultured human cancer cell lines into immunodeficient mice, where the injected cells form localized tumors that can be monitored in vivo as a measure of tumorigenic potential, growth kinetics, and treatment response. These models are widely used in oncology research because they allow reproducible tumor formation and enable comparative assessment of tumor growth between different cell lines or genetic manipulations in a controlled in vivo microenvironment. Subcutaneous implantation of cancer cells in immunodeficient mice is a standard approach for evaluating tumor growth behavior and therapeutic response across multiple cancer types, including prostate, esophageal, pancreatic, and colon cancer models.
Purity & Documentation
References
[1]. Schon O, et al. Binding of p53-derived ligands to MDM2 induces a variety of long range conformational changes. J Mol Biol. 2004;336(1):197-202. [Content Brief]
[2]. Michl J, et al. PNC-28, a p53-derived peptide that is cytotoxic to cancer cells, blocks pancreatic cancer cell growth in vivo. Int J Cancer. 2006;119(7):1577-1585. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
p53 (17-26) Related Classifications
HY-P1755 Related Classifications
Powered by Bioz